Evidence map›Paper›PMID 26712692›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.

Luke D Rothermel, Arvind C Sabesan, Daniel J Stephens, Smita S Chandran, Biman C Paria, Abhishek K Srivastava, Robert Somerville, John R Wunderlich, Chyi-Chia R Lee, Liqiang Xi and 5 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05047276 (Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma), which is not on this map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05047276 phase1 / phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma

TypeinterventionalSponsorJosé María Piulats RodríguezRan2021 to 2024Enrolled16ConditionsUveal Melanoma, MetastaticArmsAloCelyvir
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Uveal melanoma: Recent advances in immunotherapy.World journal of clinical oncology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Luke D RothermelSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Arvind C SabesanSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Daniel J StephensSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Smita S ChandranSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Biman C PariaSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abhishek K SrivastavaSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Robert SomervilleSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
John R WunderlichSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Chyi-Chia R LeeLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Liqiang XiLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Trinh H PhamLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mark RaffeldLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Parthav JailwalaAdvanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research Inc., Frederick, Maryland.
Manjula KasojiAdvanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research Inc., Frederick, Maryland.
Udai S KammulaSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. udai_kammula@nih.gov.
National Cancer Institute · USNational Institutes of Health · US

Funding

Molecular Diagnostics Core LaboratoryZICBC011079 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI XI, LIQIANG · 2009 to 2025
$33.8M
CCR Collaborative Bioinformatics ResourceZICBC011532 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALIK, MARIAM · 2013 to 2025
$33.7M
High Throughput Isolation of Antigen Specific T-cells for Cancer TherapyZIABC010766 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAMMULA, UDAI S · 2009 to 2017
$5.5M
Immunotherapy Strategies for Uveal MelanomaZIABC010649 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAMMULA, UDAI S · 2009 to 2017
$3.7M
Immunotherapy Strategies for Gastrointestinal and Hepatocellular CancerZ01BC010649 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAMMULA, UDAI S · 2005 to 2008
$1.1M
High Throughput Isolation of Antigen Specific T-cells for Cancer TherapyZ01BC010766 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KAMMULA, UDAI S · 2007 to 2008
$1.1M
Intramural NIH HHS Z01 BC010649Intramural NIH HHS Z01 BC010766
6 · The paper itself

Abstract

purposeUveal melanoma is a rare melanoma variant with no effective therapies once metastases develop. Although durable cancer regression can be achieved in metastatic cutaneous melanoma with immunotherapies that augment naturally existing antitumor T-cell responses, the role of these treatments for metastatic uveal melanoma remains unclear. We sought to define the relative immunogenicity of these two melanoma variants and determine whether endogenous antitumor immune responses exist against uveal melanoma. EXPERIMENTAL

designWe surgically procured liver metastases from uveal melanoma (n = 16) and cutaneous melanoma (n = 35) patients and compared the attributes of their respective tumor cell populations and their infiltrating T cells (TIL) using clinical radiology, histopathology, immune assays, and whole-exomic sequencing.

resultsDespite having common melanocytic lineage, uveal melanoma and cutaneous melanoma metastases differed in their melanin content, tumor differentiation antigen expression, and somatic mutational profile. Immunologic analysis of TIL cultures expanded from these divergent forms of melanoma revealed cutaneous melanoma TIL were predominantly composed of CD8(+) T cells, whereas uveal melanoma TIL were CD4(+) dominant. Reactivity against autologous tumor was significantly greater in cutaneous melanoma TIL compared with uveal melanoma TIL. However, we identified TIL from a subset of uveal melanoma patients which had robust antitumor reactivity comparable in magnitude with cutaneous melanoma TIL. Interestingly, the absence of melanin pigmentation in the parental tumor strongly correlated with the generation of highly reactive uveal melanoma TIL.

conclusionsThe discovery of this immunogenic group of uveal melanoma metastases should prompt clinical efforts to determine whether patients who harbor these unique tumors can benefit from immunotherapies that exploit endogenous antitumor T-cell populations. Clin Cancer Res; 22(9); 2237-49. ©2015 AACR.

Indexed as

AdolescentAdultAgedAntigens, NeoplasmCD8-Positive T-LymphocytesCutaneous Malignant MelanomaCytotoxicity, ImmunologicFemaleHumansLymphocyte ActivationLymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedRetrospective StudiesSkin NeoplasmsAntigens, Neoplasm

Identifiers

PMID26712692
PMCPMC4854785
OpenAlexW2217683734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.